180 Life Sciences Corp (OQ:ATNF)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Mar 14, 2024 08:30 am ET

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance...

Feb 26, 2024 07:00 am ET

180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-19 (the “Reverse Stock Split”). The Reverse...

Dec 04, 2023 09:00 am ET

180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value....

Nov 28, 2023 09:00 am ET

180 Life Sciences Announces Review of Strategic Alternatives

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder...

Aug 14, 2023 04:29 pm ET

180 Life Sciences Corp. Announces Closing of $3 Million Public Offering

180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced public offering of 4,615,385 shares of the Company’s common stock (or...

Aug 10, 2023 08:46 am ET

180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering

180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the pricing of a public offering of 4,615,385 shares of the Company’s common stock (or common stock equivalents in...

Aug 07, 2023 09:00 am ET

180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that an agreement has been reached with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital,...

Aug 03, 2023 08:00 am ET

180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request Wit

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain announces that it...

Jul 31, 2023 08:00 am ET

180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite

180 Life Sciences Corp. (NASDAQ: ATNF) (“180LS” or the “Company”), today announced the filing of a provisional patent describing the novel combination of CBD, or an analog thereof, with glucagon related peptide-1 (GLP-1) agonists to address the...

Apr 10, 2023 04:30 pm ET

180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement

180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced issuance and sale of 1,570,680 shares of the Company’s common stock (or...

Apr 05, 2023 01:00 pm ET

180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement

180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor, for...

Feb 27, 2023 08:30 am ET

180 Life Sciences Announces Presentation at the Gordon Conference

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that Professor Jagdeep Nanchahal has been selected to present at the Gordon Research Conference on “Physiological and Disease Relevance and Underlying...

Feb 23, 2023 07:30 am ET

180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a Notice of Allowance for United States (US) patent application number...

Feb 22, 2023 04:30 pm ET

180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced closure to recruitment of men and women across England with early stage Frozen shoulder for a trial to determine the feasibility of conducting a large...

Jan 25, 2023 08:45 am ET

180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Treatments for early stage Dupuytren’s disease: an evidence-based approach’ in The Journal of Hand Surgery...

Jan 17, 2023 08:00 am ET

180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company has engaged Kinexum, a strategic advisory firm, to support the Company in submitting a Marketing Authorisation Application (MAA) for...

Jan 10, 2023 01:56 pm ET

Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)

Newman Ferrara LLP announced today that it has an ongoing investigation into actions taken by officers and directors of KBL Merger Corp. IV (“KBL”), a special purpose acquisition company (“SPAC”) in connection to its merger with 180 Life Sciences Corp. (NASDAQ:ATNF) (the “Merger”) that was completed on November 6, 2020.

Jan 05, 2023 08:30 am ET

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on January 4, 2023 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full...

Jan 04, 2023 08:30 am ET

180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Dupuytren’s disease: a localized and accessible human fibrotic disorder’ in the journal Trends in Molecular...

Jan 03, 2023 11:24 am ET

Thinking about buying stock in Mullen Automotive, SWVL Holdings, 180 Life Sciences, Alibaba, or Pinterest?

NEW YORK, Jan. 3, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MULN, SWVL, ATNF, BABA, and PINS.

Dec 29, 2022 08:30 am ET

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

Dear Fellow Shareholder, As we come to the end of 2022, I am pleased to provide an update for our shareholders. In keeping with good corporate practice and US Securities and Exchange Commission (SEC) regulations, we have refrained from answering...

Dec 27, 2022 07:30 am ET

Thinking about buying stock in 180 Life Sciences, HTG Molecular, Markforged, Icecure Medical, or Rigel Pharmaceuticals?

NEW YORK, Dec. 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATNF, HTGM, MKFG, ICCM, and RIGL.

Dec 23, 2022 08:00 am ET

180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules with a...

Dec 21, 2022 07:36 am ET

Thinking about buying stock in HTG Molecular Diagnostics, 180 Life Sciences, Six Flags Entertainment, Under Armour, or Adaptive Biotechnologies?

NEW YORK, Dec. 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HTGM, ATNF, SIX, UAA, and ADPT.

Dec 20, 2022 02:11 pm ET

180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Dec 19, 2022 07:30 am ET

Thinking about buying stock in 180 Life Sciences, Viking Therapeutics, Camber Energy, New Oriental Education & Tech, or Rigel Pharmaceuticals?

NEW YORK, Dec. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATNF, VKTX, CEI, EDU, and RIGL.

Dec 16, 2022 09:00 am ET

180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will effect a one-for-20 reverse stock split (“reverse split”) of its common stock, $0.0001 par value per share (“Common Stock”), that will...

Nov 30, 2022 05:00 pm ET

180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company and its regulatory consultants from the US and the UK, met with the UK Medicines and Healthcare products Regulatory Agency (MHRA)...

Nov 21, 2022 08:30 am ET

180 Life Sciences to Participate in A.G.P.’s Virtual Biotech Conference to be Held November 30 – December 1, 2022

Nov 15, 2022 12:37 pm ET

CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease

A correction has been issued for the release disseminated under the same headline on Thursday, November 15th by 180 Life Sciences Corp. An embedded link has been added to the 5th paragraph. The complete and corrected release follows. 180 Life...

Nov 15, 2022 08:00 am ET

Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company today announced that researchers at Oxford Population Health’s Health Economics Research Centre and the Kennedy Institute of...

Sep 26, 2022 08:30 am ET

180 Life Sciences Issues Letter to Stockholders

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody. Dear Fellow Stockholder,...

Aug 22, 2022 08:30 am ET

180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company announced that the first patient has been randomized in the clinical trial to evaluate anti-tumor necrosis factor (TNF) for...

Jul 27, 2022 08:30 am ET

180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative De

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that a team led by researchers at University of Oxford have been awarded a grant from the National Institute for...

Jul 21, 2022 08:00 am ET

180 Life Sciences Corp. Announces Closing of $6.5 Million Registered Direct Offering

180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously-announced registered direct offering to a single healthcare-focused U.S....

Jul 18, 2022 08:30 am ET

180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering

Jun 22, 2022 04:05 pm ET

180 Life Sciences Corp. Issues Letter to Stockholders

180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the "Company"), a clinical-stage biotechnology company today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody. Dear Fellow...

Jun 14, 2022 04:15 pm ET

180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease

Jun 02, 2022 09:31 am ET

Thinking about buying stock in 180 Life Sciences, Obsidian Energy, Tonix Pharmaceuticals, Nio, or SoFi Technologies?

NEW YORK, June 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATNF, OBE, TNXP, NIO, and SOFI.

May 31, 2022 08:30 am ET

180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren’s Disease

May 02, 2022 08:00 am ET

REPEAT - 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

Apr 29, 2022 06:32 pm ET

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

Feb 17, 2022 08:30 am ET

180 Life Sciences Corp. Forms Scientific Advisory Board

Jan 31, 2022 08:00 am ET

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released the...

Dec 28, 2021 11:00 am ET

180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022

Dec 15, 2021 08:15 am ET

180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases

Dec 06, 2021 08:15 am ET

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results

Dec 01, 2021 02:45 pm ET

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial

Dec 01, 2021 08:00 am ET

Thinking about buying stock in Applied UV, Ardelyx, VBI Vaccines, Aemetis, or 180 Life Sciences?

NEW YORK, Dec. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUVI, ARDX, VBIV, AMTX, and ATNF.

Nov 29, 2021 07:30 am ET

Thinking about buying stock in Adagio Therapeutics, 180 Life Sciences, InMed Pharmaceuticals, Beyondspring, or Inovio Pharmaceuticals?

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADGI, ATNF, INM, BYSI, and INO.

Nov 22, 2021 08:30 am ET

180 Life Sciences Corp. Expands Patent Portfolio

Nov 18, 2021 08:15 am ET

180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium

Nov 03, 2021 12:06 pm ET

180 Life Sciences Corp. Names Quan A. Vu Chief Operating Officer/Chief Business Officer

Oct 26, 2021 08:30 am ET

180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal Molecules

Sep 30, 2021 08:30 am ET

180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio

Sep 20, 2021 08:00 am ET

Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications

Aug 30, 2021 08:30 am ET

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders

180 Life Sciences Corp. (NASDAQ: ATNF, the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b clinical trial, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis...

Aug 24, 2021 08:30 am ET

180 Life Sciences Corp. Announces Closing of $15.0 Million Private Placement

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced...

Aug 19, 2021 09:00 am ET

180 Life Sciences Corp. Announces $15.0 Million Private Placement

180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that...

Aug 02, 2021 08:00 am ET

Chairman of the 180 Life Sciences Clinical Advisory Board, Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn S

Jul 29, 2021 08:00 am ET

180 Life Sciences to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference

Jul 28, 2021 08:15 am ET

180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue

Jul 20, 2021 08:00 am ET

180 Life Sciences Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Jul 12, 2021 09:51 am ET

180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2)

Jul 07, 2021 08:00 am ET

180 Life Sciences Expands Scientific Fibrosis Platform with Collagen VI as a Driver and Disease Biomarker in Human Fibrosis Published in the FEBS Journal

Jun 28, 2021 08:15 am ET

180 Life Sciences Joins Russell Microcap® Index

Jun 28, 2021 08:00 am ET

180 Life Sciences Files Plan with Nasdaq Related to Delayed Quarterly Report on Form 10-Q and Form 10-K

Jun 10, 2021 09:12 am ET

180 Life Sciences Corp. Announces the Appointment of Pamela Marrone, PhD and Frank Knuettel II, MBA to Board of Directors

Jun 01, 2021 08:00 am ET

180 Life Sciences Corp. to Present at LD Micro Invitational XI

May 28, 2021 08:00 am ET

180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors

May 21, 2021 04:45 pm ET

180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Quarterly Report on Form 10-Q

Apr 20, 2021 08:00 am ET

180 Life Sciences Corp. Announces Collection of All Patient Data for Phase 2b Dupuytren’s Disease Trial

Apr 19, 2021 05:00 pm ET

180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Annual Report on Form 10-K

Apr 14, 2021 08:15 am ET

180 Life Sciences Corp. Congratulates Dr. Lynn Williams on International Dupuytren Award 2021

Mar 26, 2021 08:30 am ET

180 Life Sciences Corp. (NASDAQ: ATNF) Recognized R&D Pioneers in Anti-Inflammatory Therapeutics

NetworkNewsAudio – 180 Life Sciences Corp. (NASDAQ: ATNF) announces the availability of a broadcast titled, “Controlling Inflammation to Stop Disease.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the...

Mar 25, 2021 08:30 am ET

180 Life Sciences Corp. (NASDAQ: ATNF) in Hot Pursuit of New Anti-Inflammatory Blockbusters

via InvestorWire — 180 Life Sciences Corp. (NASDAQ: ATNF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and...

Mar 24, 2021 08:30 am ET

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders

180 Life Sciences Corp. (NASDAQ: ATNF, the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3 clinical trial, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases,...

Mar 08, 2021 01:30 pm ET

180 Life Sciences Corp. to Present at Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC

180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases,...

Feb 24, 2021 04:00 pm ET

180 Life Sciences Corp. Announces Closing of $11.7 Million Private Placement

Feb 19, 2021 09:00 am ET

180 Life Sciences Corp. Announces $11.7 Million Private Placement

Jan 11, 2021 08:00 am ET

180 Life Sciences Corp. to Present at the Biotech Showcase(TM) Digital 2021 Conference

Menlo Park, California--(Newsfile Corp. - January 11, 2021) - 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that the Company will present at the Biotech Showcase™ Digital 2021 Conference.

Jan 05, 2021 02:50 pm ET

180 Life Sciences Corp. to Present at the H.C. Wainwright Bioconnect 2021 Conference

Dec 03, 2020 11:08 am ET

180 Life Sciences Corp. to Present at the 13th Annual LD Micro Main Event Conference on Tuesday, December 15th at 1:40 PM EST

180 Life Sciences Corp. (NASDAQ: ATNF) ("180 Life Sciences" or "the Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory...

Nov 24, 2020 10:00 am ET

Ad blocking detected

180 Life Sciences Corp (OQ:ATNF)

Business Focus: Bio Therapeutic Drugs